Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics
Neuro-Oncology · 2023
DOI: 10.1093/neuonc/noac132 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Neuro-Oncology, 2023. Verfasst von Kee Kiat Yeo und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Boston, MA, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioma, Astrocytoma. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Pediatric Brain Tumor Foundation.
Abstract (Originalsprache)
Background
The incidence and biology of IDH1/2 mutations in pediatric gliomas are unclear. Notably, current treatment approaches by pediatric and adult providers vary significantly. We describe the frequency and clinical outcomes of IDH1/2-mutant gliomas in pediatrics.
Methods
We performed a multi-institutional analysis of the frequency of pediatric IDH1/2-mutant gliomas, identified by next-generation sequencing (NGS). In parallel, we retrospectively reviewed pediatric IDH1/2-mutant gliomas, analyzing clinico-genomic features, treatment approaches, and outcomes.
Results
Incidence: Among 851 patients with pediatric glioma who underwent NGS, we identified 78 with IDH1/2 mutations. Among patients 0–9 and 10–21 years old, 2/378 (0.5%) and 76/473 (16.1%) had IDH1/2-mutant tumors, respectively. Frequency of IDH mutations was similar between low-grade glioma (52/570, 9.1%) and high-grade glioma (25/277, 9.0%). Four tumors were graded as intermediate histologically, with one IDH1 mutation. Outcome: Seventy-six patients with IDH1/2-mutant glioma had outcome data available. Eighty-four percent of patients with low-grade glioma (LGG) were managed observantly without additional therapy. For low-grade astrocytoma, 5-year progression-free survival (PFS) was 42.9% (95%CI:20.3–63.8) and, despite excellent short-term overall survival (OS), numerous disease-related deaths after year 10 were reported. Patients with high-grade astrocytoma had a 5-year PFS/OS of 36.8% (95%CI:8.8–66.4) and 84% (95%CI:50.1–95.6), respectively. Patients with oligodendroglioma had excellent OS.
Conclusions
A subset of pediatric gliomas is driven by IDH1/2 mutations, with a higher rate among adolescents. The majority of patients underwent upfront observant management without adjuvant therapy. Findings suggest that the natural history of pediatric IDH1/2-mutant glioma may be similar to that of adults, though additional studies are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Boston, MA, USA.
- Harvard Medical School, Boston, MA, USA.
- Department of Pathology, Boston Children's Hospital, Boston, MA, USA.
- Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA,USA.
- Division of Genomic Diagnostics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
ORCID-Profile: Kee Kiat Yeo, Sanda Alexandrescu, Jianling Ji, Tom Rosenberg, Eli L Diamond
Förderung
- NCI NIH HHS
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology
- Pediatric Brain Tumor Foundation
- PLGA Fund
- David Andrysiak CRA
Zitieren
APA
Yeo, K. K., Alexandrescu, S., Cotter, J. A., Vogelzang, J., Bhave, V., Li, M. M., Ji, J., Benhamida, J. K., Rosenblum, M. K., Bale, T. A., Bouvier, N., Kaneva, K., Rosenberg, T., Lim-Fat, M. J., Ghosh, H., Martinez, M., Aguilera, D., Smith, A., Goldman, S., …, & Wright, K. D. (2023). Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics. Neuro-Oncology. https://doi.org/10.1093/neuonc/noac132
Vancouver
Yeo KK, Alexandrescu S, Cotter JA, Vogelzang J, Bhave V, Li MM, et al. Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics. Neuro-Oncology. 2023. doi:10.1093/neuonc/noac132
BibTeX
@article{Yeo2023,
author = {Yeo, Kee Kiat and Alexandrescu, Sanda and Cotter, Jennifer A and Vogelzang, Jayne and Bhave, Varun and Li, Marilyn M and Ji, Jianling and Benhamida, Jamal K and Rosenblum, Marc K and Bale, Tejus A and Bouvier, Nancy and Kaneva, Kristiyana and Rosenberg, Tom and Lim-Fat, Mary Jane and Ghosh, Hia and Martinez, Migdalia and Aguilera, Dolly and Smith, Amy and Goldman, Stewart and Diamond, Eli L and Gavrilovic, Igor and MacDonald, Tobey J and Wood, Matthew D and Nazemi, Kellie J and Truong, AiLien and Cluster, Andrew and Ligon, Keith L and Cole, Kristina and Bi, Wenya Linda and Margol, Ashley S and Karajannis, Matthias A and Wright, Karen D},
title = {Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics},
journal = {Neuro-Oncology},
year = {2023},
doi = {10.1093/neuonc/noac132}
}
EUVIMED